Hopp til hovedinnhold
Toggle navigation
Live markets
Search
Search
Search
Search
My profile
My Subscriptions
Watchlists
Quote alerts
Create account
Sign in
NB
FR
EN
PT
NL
NB
DE
IT
Hjem
Company Press Releases
Company press releases
Abonner
Filtre
Filtre
Oppdater
Nullstill
Icon After
Dato
Toggle Visibility
Alle
I dag
Denne uken
Denne måneden
Tilpasset datosøk
Fra
Til
Kategori
Toggle Visibility
Alliances and agreements
Annen informasjonspliktig regulatorisk informasjon
Change in Capital
Commercial operations
Commercial results
Corporate life
Dividend
Eks.dato
Endringer i rettighetene til aksjer / verdipapirer
Flagging
General meeting / Board Meeting
Halvårsrapporter og revisjonsberetninger / uttalelser om forenklet revisorkontroll
Ikke-informasjonspliktige pressemeldinger
Income
Innsideinformasjon
Joint venture
Journal / appointments
Kapital- og stemmerettsendringer
Legal
Meetings / events
Meldepliktig handel for primærinnsidere
Mergers, Acquiqitions, Transferts
New
New establishment
News contracts
Other financial transaction
Other subject
Polls / Surveys
Products and services
Prospekt / opptaksdokument
Rapportering om betaling til myndigheter (land-for-land rapportering)
Rating
Renteregulering
Sales
Share history
Share introduction and issues
Takeover bids
Trends / Analyses
Utsteders meldeplikt ved handel i egne aksjer
Valg av hjemstat
Årsrapporter og revisjonsberetninger
Leverandør
Toggle Visibility
ActusNewsWire
BusinessWire
EQS Group
Euronext
GlobeNewswire
Les Echos
Marketwire
Modular Finance
Oslo Børs Newspoint
PR Newswire
Viser 1 - 50 av 89 resultater
Tid
Selskap
Tittel
Sektor
Kategori
25 Apr 2024
18:00 CEST
AELIS FARMA
Aelis Farma: Availability of the 2023 Universal Registration Document
20103010 Biotechnology
Legal
25 Apr 2024
18:00 CEST
AELIS FARMA
Aelis Farma : Mise à disposition du Document d’Enregistrement Universel 2023
20103010 Biotechnology
Legal
18 Apr 2024
18:00 CEST
AELIS FARMA
Aelis Farma annonce la dernière visite du dernier patient (Last Patient Last Visit ou LPLV) de l’étude de phase 2b avec AEF0117 dans le traitement de l’addiction au cannabis
20103010 Biotechnology
Other subject
18 Apr 2024
18:00 CEST
AELIS FARMA
Aelis Farma Announces the Last Patient, Last Visit in its Clinical Phase 2b Trial with AEF0117 for the Treatment of Cannabis Use Disorder
20103010 Biotechnology
Other subject
05 Apr 2024
19:00 CEST
AELIS FARMA
Aelis Farma : Apport complémentaire au contrat de liquidité conclu avec Invest Securities
20103010 Biotechnology
Legal
02 Apr 2024
17:45 CEST
AELIS FARMA
Aelis Farma Reports Its 2023 Annual Financial Resultsand Confirms Its 2024 Outlook
20103010 Biotechnology
Income
02 Apr 2024
17:45 CEST
AELIS FARMA
Aelis Farma publie ses résultats financiers annuels 2023 et confirme ses perspectives 2024
20103010 Biotechnology
Income
06 Feb 2024
19:45 CET
AELIS FARMA
Aelis Farma : Apport complémentaire au contrat de liquidité conclu avec Invest Securities
20103010 Biotechnology
Legal
30 Jan 2024
18:00 CET
AELIS FARMA
Aelis Farma annonce son calendrier financier pour l’exercice 2024
20103010 Biotechnology
Meetings / events
30 Jan 2024
18:00 CET
AELIS FARMA
Aelis Farma Announces Its 2024 Financial Calendar
20103010 Biotechnology
Meetings / events
17 Jan 2024
18:23 CET
AELIS FARMA
Aelis Farma Strengthens its Leadership Team with the Appointment of Arsène Guekam as Chief Corporate Development Officer
20103010 Biotechnology
Corporate life
17 Jan 2024
18:23 CET
AELIS FARMA
Aelis Farma renforce sa direction avec la nomination de Arsène Guekam en tant que Chief Corporate Development Officer
20103010 Biotechnology
Corporate life
09 Jan 2024
18:29 CET
AELIS FARMA
Aelis Farma annonce la finalisation du recrutement des patients pour l’étude de phase 2b avec AEF0117 dans le traitement de l’addiction au cannabis
20103010 Biotechnology
Other subject
09 Jan 2024
18:29 CET
AELIS FARMA
Aelis Farma Announces Completion of Patient Randomization for Phase 2b Study with AEF0117 for the Treatment of Cannabis Addiction
20103010 Biotechnology
Other subject
03 Jan 2024
19:00 CET
AELIS FARMA
Aelis Farma : Bilan semestriel du contrat de liquidité et apport complémentaire au contrat de liquidité conclu avec Invest Securities
20103010 Biotechnology
Other subject
07 Nov 2023
18:31 CET
AELIS FARMA
Aelis Farma annonce les résultats positifs d’études non-cliniques réglementaires pour l'entrée de son premier CB1-SSi, AEF0117, en étude clinique de phase 3 dans le traitement des troubles liés à la consommation excessive de cannabis
20103010 Biotechnology
New
07 Nov 2023
18:31 CET
AELIS FARMA
Aelis Farma Announces Positive Results of Non-clinical Studies Required by Regulatory Agencies to Enter Its First CB1-SSi, AEF0117, in Phase 3 Clinical Trial for the Treatment of Cannabis Use Disorder
20103010 Biotechnology
New
27 Sep 2023
19:07 CEST
AELIS FARMA
Aelis Farma : Apport complémentaire au contrat de liquidité conclu avec Invest Securities
20103010 Biotechnology
Legal
26 Sep 2023
18:00 CEST
AELIS FARMA
Aelis Farma: Availability of the 2023 Half-Year Financial Report
20103010 Biotechnology
Legal
26 Sep 2023
18:00 CEST
AELIS FARMA
Aelis Farma: Mise à disposition du rapport financier semestriel 2023
20103010 Biotechnology
Legal
25 Sep 2023
18:00 CEST
AELIS FARMA
Aelis Farma Publishes Half-Year Financial Results for 2023 and Confirms Its Development Objectives
20103010 Biotechnology
Income
25 Sep 2023
18:00 CEST
AELIS FARMA
Aelis Farma publie ses résultats financiers semestriels 2023 et confirme ses perspectives de développement
20103010 Biotechnology
Income
29 Aug 2023
18:00 CEST
AELIS FARMA
Aelis Farma : Apport complémentaire au contrat de liquidité conclu avec Invest Securities
20103010 Biotechnology
Legal
28 Aug 2023
17:45 CEST
AELIS FARMA
Pier Vincenzo Piazza, CEO of Aelis Farma, Receives the Distinguished Achievement Award from the European Behavioural Pharmacology Society (EBPS)
20103010 Biotechnology
Other subject
28 Aug 2023
17:45 CEST
AELIS FARMA
Pier Vincenzo Piazza, Directeur Général d’Aelis Farma, reçoit le Prix d’Excellence décerné par la Société européenne de pharmacologie comportementale (EBPS)
20103010 Biotechnology
Other subject
20 Jul 2023
17:45 CEST
AELIS FARMA
Aelis Farma participe à la 10ème édition de la Gordon Research Conference portant sur le rôle des récepteurs cannabinoïdes dans les maladies du système nerveux central
20103010 Biotechnology
New
20 Jul 2023
17:45 CEST
AELIS FARMA
Aelis Farma Takes Part in the 10th Edition of the Gordon Research Conference on the Role of Cannabinoid Receptors in Central Nervous System Disorders
20103010 Biotechnology
New
05 Jul 2023
07:00 CEST
AELIS FARMA
Aelis Farma Receives a Positive Recommendation From the DSMB to Continue, With No Modification to the Protocol, the Phase 2b Clinical Study With AEF0117 in Cannabis Addiction
20103010 Biotechnology
New
05 Jul 2023
07:00 CEST
AELIS FARMA
Aelis Farma reçoit l’avis positif du DSMB pour la poursuite sans changement au protocole de son étude clinique de phase 2b avec AEF0117 dans l’addiction au cannabis
20103010 Biotechnology
New
04 Jul 2023
18:03 CEST
AELIS FARMA
Aelis Farma : Bilan semestriel du contrat de liquidité
20103010 Biotechnology
Other subject
03 Jul 2023
17:45 CEST
AELIS FARMA
AELIS FARMA : Information relative au nombre total de droits de vote et d’actions composant le capital social
20103010 Biotechnology
Share history
21 Jun 2023
18:00 CEST
AELIS FARMA
Aelis Farma: Availability of the Description of the Share Buyback Program
20103010 Biotechnology
Share history
21 Jun 2023
18:00 CEST
AELIS FARMA
Aelis Farma : Mise à disposition du descriptif du programme de rachat d’actions
20103010 Biotechnology
Share history
12 Jun 2023
07:00 CEST
AELIS FARMA
Des données précliniques montrant une efficacité de AEF0217 dans un modèle génétique murin du trouble du spectre de l'autisme ont été présentées lors de la 2ème Conférence Européenne sur le Syndrome de Phelan-McDermid
20103010 Biotechnology
New
12 Jun 2023
07:00 CEST
AELIS FARMA
Preclinical Data Demonstrating the Efficacy of AEF0217 in a Genetic Mouse Model of Autism Spectrum Disorder Has Been Presented at the 2nd European Conference on Phelan-McDermid Syndrome
20103010 Biotechnology
New
08 Jun 2023
17:15 CEST
AELIS FARMA
Nature Medicine publie un article décrivant la nouvelle classe pharmacologique découverte par Aelis Farma et les données cliniques de phase 2a pour le traitement des troubles liés à la consommation excessive de cannabis
20103010 Biotechnology
New
08 Jun 2023
17:15 CEST
AELIS FARMA
Nature Medicine Publishes Discovery of New Pharmacological Class by Aelis Farma, Phase 2a Study of First Drug Candidate for Cannabis Use Disorder
20103010 Biotechnology
New
05 Jun 2023
18:52 CEST
AELIS FARMA
Aelis Farma : Apport complémentaire au contrat de liquidité conclu avec Invest Securities
20103010 Biotechnology
Legal
25 May 2023
18:00 CEST
AELIS FARMA
Communication des résultats de l’Assemblée générale mixte d’Aelis Farma du 24 mai 2023
20103010 Biotechnology
General meeting / Board Meeting
25 May 2023
18:00 CEST
AELIS FARMA
Results of Aelis Farma Combined General Meeting of May 24, 2023
20103010 Biotechnology
General meeting / Board Meeting
02 May 2023
18:00 CEST
AELIS FARMA
Aelis Farma : Assemblée générale mixte du 24 mai 2023 : mise à disposition des documents préparatoires et modalités de participation et de vote
20103010 Biotechnology
Legal
02 May 2023
18:00 CEST
AELIS FARMA
Aelis Farma: Combined General Meeting of May 24, 2023: Availability of Preparatory Documents and Participation and Voting Procedures
20103010 Biotechnology
Legal
27 Apr 2023
18:00 CEST
AELIS FARMA
Aelis Farma : Mise à disposition du Document d’Enregistrement Universel 2022
20103010 Biotechnology
Legal
27 Apr 2023
18:00 CEST
AELIS FARMA
Aelis Farma: Publication of the 2022 Universal Registration Document
20103010 Biotechnology
Legal
24 Apr 2023
18:33 CEST
AELIS FARMA
Degroof Petercam initie à « l’Achat » la couverture d’Aelis Farma
20103010 Biotechnology
Other subject
24 Apr 2023
18:33 CEST
AELIS FARMA
Degroof Petercam Initiates the Coverage of Aelis Farma With a “Buy” Recommendation
20103010 Biotechnology
Other subject
03 Apr 2023
17:45 CEST
AELIS FARMA
Aelis Farma Reports Its 2022 Annual Financial Results and Confirms Its 2023 Outlook
20103010 Biotechnology
Income
03 Apr 2023
17:45 CEST
AELIS FARMA
Aelis Farma publie ses résultats financiers annuels 2022 et confirme ses perspectives 2023
20103010 Biotechnology
Income
21 Mar 2023
17:45 CET
AELIS FARMA
Aelis Farma Has Participated in Two Symposiums Marking World Down Syndrome Day
20103010 Biotechnology
Other subject
21 Mar 2023
17:45 CET
AELIS FARMA
Aelis Farma participe à deux symposiums à l’occasion de la Journée Mondiale de la Trisomie 21
20103010 Biotechnology
Other subject
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Sider
1
2
›
››
»
Last »
Company press releases subscription
×
To subscribe to Press releases from this issuer, visit the Subscription to Company news section in
Hjem
Markeder
Amsterdam
Cash Products
Aksjer
AEX index Stocks
AEX ESG Stocks
Indekser
Fond
Obligasjoner
ETF-er
Strukturerte produkter
Derivater
Indeksopsjoner
Indeksfutures
Aksjeopsjoner
Utbyttederivater
Aksjefutures
Quote Vendor Codes
Selskapsmeldinger
Latest
Archive
Brussel
Cash products
Aksjer
Euronext regulated
Euronext Growth
Euronext Access
Expert Market
BEL 20 Stocks
Indekser
Obligasjoner
ETF-er
Strukturerte produkter
Derivater
Indeksfutures
Aksjeopsjoner
Aksjefutures
Utbyttederivater
Quote Vendor Codes
Selskapsmeldinger
Latest
Archive
Expert Market
Dublin
Stocks
Euronext regulated
Euronext Growth
ISEQ 20 Stocks
Indices
Funds
Bonds
Irish Government Bonds
DOL
Lisboa
Cash Products
Aksjer
Euronext regulated
Euronext Access
PSI Stocks
Indekser
Obligasjoner
Derivater
Indeksfutures
Aksjefutures
Utbyttederivater
Quote Vendor Codes
Selskapsmeldinger
Latest
Archive
Milan
Cash Products
Stocks
Euronext Milan
Euronext Growth Milan
Euronext Star Milan
Euronext Global Equity Market
EuroTLX
Trading After Hours
MIB ESG Stocks
Bonds
MOT
Euronext Access Milan
EuroTLX
Structured Products
SeDeX
EuroTLX
ETFs
Funds
Derivative products
All derivatives
Index futures
Index options
Stock options
Stock futures
Dividend derivatives
Quote Vendor Codes
IPOs
Oslo
Aksjer, renter, indekser
Aksjer
Oslo Børs
Euronext Growth
Euronext Expand
Top performers
OBX aksjer
OBX ESG aksjer
OSEBX aksjer
OSEFX Aksjer
Seafood Aksjer
Shipping Aksjer
Aksjeindekser
Obligasjoner
Oslo Børs
Nordic Alternative Bond Market
Obligasjonsindekser
ETFer
Fond
Derivater
Derivative products
Quote Vendor Codes
Selskapsmeldinger
Latest
Archive
Finanskalender
Primærinnsidere
Paris
Cash Products
Aksjer
Euronext regulated
Euronext Growth
Euronext Access
CAC 40 Stocks
CAC 40 ESG Stocks
Indekser
Obligasjoner
ETF-er
Strukturerte produkter
Derivater
Indeksfutures
Indeksopsjoner
Aksjeopsjoner
Aksjefutures
Utbyttederivater
Quote Vendor Codes
Selskapsmeldinger
Latest
Archive
Aksjer
All Markets directories
All Markets
Euronext regulated
Euronext Growth
Euronext Access
Euronext Expand
Euronext Global Equity Market
EuroTLX
Trading After Hours
Selskapsmeldinger
Latest
Archive
Nye aksjenoteringer
Alle aksjenoteringer
Euronext Growth advisors
Euronext Tech Leaders
Family business
Indekser
Directory
Grønne indekser
Indices documents
Indices news
Indekser høringer
Kontakter Euronext-indekser
ETF-er
Directory
Grønne ETF-er
Fond
Directory
ESG Funds
Oslo Mutual Funds
Obligasjoner
Grønne obligasjoner
1.5° Bonds
All Markets directories
All Markets
Amsterdam
Brussels
Dublin
Lisbon
Oslo
Milan
Paris
Strukturerte produkter
Directory / search
Bid-Only trading status
Trading Turbos in the Netherlands
Derivater
Indeksfutures
Indeksopsjoner
Aksjeopsjoner
Aksjefutures
Utbyttederivater
ETF opsjoner
Kontraktsspesifikasjoner
Tick sizes
Rapportering av handler
Leverandørkoder markedsdata
Råvarer
Quotes
Quotes snapshot
Milling Wheat futures
Rapeseed futures
Corn futures
European Durum Wheat Futures
Milling Wheat options
Rapeseed options
Corn options
Bortfallskalendre
Bortfall
Wholesale Trading
Commitments of Traders (CoT) report
Kontraktsspesifikasjoner
Leverandørkoder markedsdata
Knowledge Centre
Bid & Ask
Options Investing E-learning
Contract Specifications
Position Management
Intrinsic Value
Premium & Valuation
Moneyness
Positions
Euronext News
Ressurser
Statistikk & rapporter
Quality of execution
Åpningstider
Kontraktsspesifikasjoner
Leverandørkoder markedsdata
Key Information Document
Class level
Product group level
Notices / Corporate actions
Cash Notices / Corporate actions
Derivatives corporate actions
All Corporate Actions
Latest
Unusual Contract Sizes, Dividends
Corporate Action Services
Corporate Action Policies
Derivatives notices
Markedshendelser
Suspenderte instrumenter
Stressed Market Conditions
Brudd på Double Cap limits
Ekstraordinære markedsforhold
Diverse meldinger
Market status
Medlemsliste
Issuers compliance
Hvor du finner hva